Anniko (penpulimab-kcqx) - Akesobio, Sino Biopharm
Focus V (anlotinib) - Advenchen
AK105 Combined With Anlotinib in Patients With Cervical Cancer (clinicaltrials.gov) - Oct 23, 2026 - P2 | N=36 | Active, not recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Sep 2024 ➔ Dec 2027 
Enrollment closed • Trial completion date • Cervical Cancer • Oncology • Solid Tumor • PD-L1
http://clinicaltrials.gov/ct2/show/NCT05137171
 
Oct 23, 2026
 
Next